Back to Journals » OncoTargets and Therapy » Volume 10

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer

Authors Aydin AM, Woldu SL, Hutchinson RC, Boegemann M, Bagrodia A, Lotan Y, Margulis V, Krabbe LM

Received 7 December 2016

Accepted for publication 10 February 2017

Published 9 March 2017 Volume 2017:10 Pages 1487—1502


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Ahmet Murat Aydin,1,* Solomon L Woldu,1,* Ryan C Hutchinson,1 Martin Boegemann,2 Aditya Bagrodia,1 Yair Lotan,1 Vitaly Margulis,1 Laura-Maria Krabbe1,2

1Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; 2Department of Urology, University of Münster Medical Center, Münster, Germany

*These authors contributed equally to this work

Abstract: Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile. We review the mechanism of action and clinical evidence of atezolizumab for metastatic urothelial bladder cancer, and discuss this drug within the context of ongoing developments in this dynamic field of immunooncology.

Keywords: atezolizumab, MPDL3280A, bladder cancer, PDL1, immunotherapy, metastatic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]